Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Mar 31, 2026

Roblox (RBLX) Stock Drops -15% in 30 Days: Margin Pressures and Analyst Cuts Weigh In

Key Takeaways

  • RBLX stock declined approximately -15% over the past 30 days amid margin pressures from higher creator payouts and analyst price target reductions.
  • Over the past quarter, shares fell around -30%, driven by post-earnings reactions to ongoing losses despite strong bookings growth, regulatory scrutiny, and slowing growth concerns.
  • Key factors include increased developer exchange (DevEx) costs, cautious 2026 profitability guidance, analyst downgrades like Citi's target cut to $90, and probes into child safety.
  • Robust user engagement with DAUs up significantly persists, but profitability challenges and competition weighed on sentiment.
  • Sector rotation away from high-growth tech names amid macro caution amplified the downward pressure.

Understanding Roblox (RBLX) and Its Place in the Market

Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.

RBLX Stock Performance: 30 Days and the Past Quarter

In the last 30 days, RBLX stock dropped -15%, moving from about $67 in early March to $56.56 by late March. The path was volatile, with a clear downward trend—sharp mid-month declines gave way to some recovery, keeping it range-bound between $52 and $59 before a modest rebound.

Looking at the quarter, the decline steepened to -30%, from $81 at the end of 2025 to $56.56. This included a post-earnings selloff in February and consistent pressure into March, lagging broader indices with elevated volatility.

Key Drivers Behind the 30-Day Decline in RBLX

The -15% slide over 30 days came largely from worries about escalating costs, especially creator payouts through DevEx, which surged 70% year-over-year to $477 million in Q4. An 8.5% payout rate hike from September squeezed margins further, and the company's guidance points to flat or declining profitability in 2026 amid investments in infrastructure, AI, and safety.

Analyst moves added to the pressure: Citi cut its price target to $90 from $105 over valuation concerns, while DA Davidson started coverage with a Neutral at $65 due to slowing growth. Sentiment stayed mixed—BofA suggested the bear case is already reflected, but the bull case remains overlooked.

Updates like ad policy changes and new board members were neutral at best, but weakness across the sector and macro caution in tech dragged it lower. Lingering regulatory noise from Dutch child safety probes under the Digital Services Act continued to cloud sentiment, even without fresh news. I also checked this using Tickeron’s AI Screener to gauge how RBLX stacks up against industry peers on these metrics.

What Shaped RBLX's Quarterly Performance

The quarter's downturn kicked off with Q4 2025 earnings on February 5: revenue climbed 43% to $1.4 billion, bookings jumped 63% to $2.2 billion—beating expectations—and DAUs hit 144 million. Yet net losses expanded to $316 million, shifting focus to persistent unprofitability and 2026 guidance of 22-26% bookings growth alongside major spending.

Regulatory heat ramped up in January, as Dutch authorities investigated child safety under the Digital Services Act, triggering a 13% one-day plunge. Downgrades piled on, with Wedbush trimming to $110 and TD Cowen issuing a Sell at $70 on fading engagement.

AI competition from tools like Google's Project Genie, plus institutional selling amid stretched valuations (even at lower levels), piled on. Broader macro shifts—like rotation out of tech and inflation fears—hit growth stocks like RBLX especially hard, magnifying the effect.

Why I Rely on Tickeron’s Trending AI Robots

In my analysis of stocks like RBLX, I often turn to Tickeron’s Trending AI Robots page, which highlights the platform's top-performing AI-driven trading bots out of hundreds available. These bots scan thousands of tickers using strategies for swing trading, day trading, and long-term positions, powered by machine learning for pattern recognition, backtested metrics like win rate, profit factor, and drawdown, plus real-time market adaptation. Curated by recent performance and relevance, they offer a transparent way to automate trades and align with specific risk levels or timeframes—something I've found useful for cross-checking my RBLX outlook.

What's Next for RBLX: Key Factors to Watch

I'm watching upcoming Q1 2026 earnings, likely in late April or early May, for progress on $1.69-$1.74 billion bookings guidance and margin insights. Trends in metaverse uptake and AI content tools could lift engagement, though EU regulatory resolutions carry downside risk.

The broader macro picture—interest rates, tech sentiment—will matter amid potential volatility. Keep an eye on strategic shifts like the 2027 ad revenue overhaul and safety upgrades such as facial age verification, which could sway costs and trust. How RBLX holds up against Meta's Horizon and AI competitors, plus institutional flows and creator payouts, will be telling.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: RBLX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RBLX in upward trend: 10-day moving average broke above 50-day moving average on September 15, 2026

The 10-day moving average for RBLX crossed bullishly above the 50-day moving average on September 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

RBLX moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where RBLX advanced for three days, in 278 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

RBLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 200 of 246 cases where RBLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for RBLX moved out of overbought territory on September 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 23 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RBLX as a result. In 57 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for RBLX turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 42 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RBLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RBLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RBLX's P/B Ratio (196.078) is very high in comparison to the industry average of (10.477). P/E Ratio (0.000) is within average values for comparable stocks, (25.481). RBLX's Projected Growth (PEG Ratio) (8.177) is very high in comparison to the industry average of (2.125). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. RBLX's P/S Ratio (5.903) is very high in comparison to the industry average of (1.575).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RBLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

Notable companies

The most notable companies in this group are NetEase (NASDAQ:NTES), Take-Two Interactive Software (NASDAQ:TTWO).

Industry description

TVs, telephones, washing machines, home speakers and even home-office equipment like computers and printers…the list is virtually endless when it comes to consumer electronics and appliances. And, with ‘smarthomes’ increasingly becoming the reality, we could see a sharp surge in high-tech gadgets (including robotic appliances) making their way into our homes– and therefore spelling plenty opportunities in the related industries. Consumers account for 70% of US GDP, and their purchases of high-functioning electronics could make significant dents in the economy’s health. Sony Corp., Whirlpool and iRobot are some of the major consumer electronics/appliances makers.

Market Cap

The average market capitalization across the Electronics/Appliances Industry is 7.06B. The market cap for tickers in the group ranges from 929 to 1.27T. SSNLF holds the highest valuation in this group at 1.27T. The lowest valued company is BHATF at 929.

High and low price notable news

The average weekly price growth across all stocks in the Electronics/Appliances Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 4%. MSGM experienced the highest price growth at 14%, while DKI experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Electronics/Appliances Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 65
Price Growth Rating: 67
SMR Rating: 75
Profit Risk Rating: 96
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
RBLX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ElectronicsAppliances

Industry
N/A
Address
3150 South Delaware Street
Phone
+1 888 858-2569
Employees
3065
Web
https://www.corp.roblox.com
Interact to see
Advertisement
I've been following Planet Labs PBC (PL) closely, and one aspect that stands out is its operation of the world's largest constellation of earth-imaging satellites. This setup delivers daily global coverage, giving it a clear edge in geospatial intelligence. The "one-to-many" model allows for scalable economics, setting it apart from legacy providers that depend on exclusive image sales. The platform combines satellite data with AI-driven analytics, targeting sectors such as agriculture, defense, forestry, and insurance.
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.
I've been keeping an eye on KDK, and it's clear the company is well-positioned in the autonomous vehicle space, with a focus on AI-powered solutions for long-haul trucking, industrial applications, and defense. Founded in 2018 and based in Mountain View, California, Kodiak AI develops the Kodiak Driver—a modular, vehicle-agnostic virtual driver that integrates advanced AI software with hardware to enable driverless operations. This platform tackles key challenges like U.S. truck driver shortages and safety concerns, where human error accounts for over 85% of crashes.
SE stock declined -21% over the past 30 days, primarily triggered by a Q4 2025 earnings EPS miss despite revenue beat, leading to a sharp 16% single-day drop. Over the past quarter, the stock fell -37%, reflecting sustained pressure from analyst price target cuts and concerns over rising growth investments.
As I review the cybersecurity space, PANW stands out with its commanding position, holding a 28.4% share in network security as of 2024. This leadership stems from its evolution from point solutions to a unified platform that includes Strata for network security, Prisma for cloud and SASE, and Cortex for AI-powered security operations. The platformization strategy is key here—it encourages customers to consolidate their fragmented tools, which reduces complexity and costs while driving NGS ARR growth. In Q2 FY2026, NGS ARR rose 33% year-over-year to $6.3 billion.
TaskUs, Inc. (TASK) stands out as a leading provider of outsourced digital services and next-generation customer experience solutions. The company focuses on digital customer experience (Digital CX), trust and safety (monitoring user-generated content for compliance), and artificial intelligence (AI) services such as data labeling and annotation for machine learning models. From its headquarters in New Braunfels, Texas, TaskUs serves high-growth sectors like social media, e-commerce, gaming, streaming, food delivery, ride-sharing, technology, financial services, and healthcare.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Lam Research Corporation stands out as a leading supplier of semiconductor processing equipment essential for fabricating integrated circuits. The company designs, manufactures, markets, refurbishes, and services tools for deposition, etch, and clean processes, serving major chipmakers across the United States, China, Korea, Taiwan, Japan, and Europe. At its core, Lam's business revolves around innovative systems like ALTUS for film deposition and SABRE for electrochemical deposition, which are vital for advanced nodes in AI, memory, and logic chips.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
NKE shares are tumbling approximately 11% in premarket trading on April 1, 2026, sliding to near nine-year lows after the previous close of $52.82. The primary catalyst is Nike's weak Q4 fiscal 2026 guidance: management projected a 2%–4% revenue decline, sharply missing analyst expectations of approximately 1.9% growth.